Retro Biosciences, a longevity startup funded by Sam Altman, is testing an Alzheimer's drug called RTR 242. The pill aims to enhance cellular recycling processes that decline with age, potentially addressing neurodegenerative diseases. Early clinical trials in Australia have shown no major side effects in healthy volunteers, and the company is working to determine the optimal dosage.
Related Articles
Don't miss out on breaking stories and in-depth articles.